Apellis Pharmaceuticals, Inc. (APLS)

NASDAQ: APLS · IEX Real-Time Price · USD
68.30
+5.30 (8.41%)
At close: Sep 30, 2022 4:00 PM
67.84
-0.46 (-0.67%)
After-hours: Sep 30, 2022 7:27 PM EDT
8.41%
Market Cap 7.50B
Revenue (ttm) 96.64M
Net Income (ttm) -638.42M
Shares Out 109.87M
EPS (ttm) -7.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,101,584
Open 64.99
Previous Close 63.00
Day's Range 64.99 - 69.89
52-Week Range 30.17 - 70.00
Beta 1.51
Analysts Buy
Price Target 79.68 (+16.7%)
Earnings Date Nov 7, 2022

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment ... [Read more...]

Industry Biotechnology
IPO Date Nov 9, 2017
CEO Cedric Francois
Employees 476
Stock Exchange NASDAQ
Ticker Symbol APLS
Full Company Profile

Financial Performance

In 2021, APLS's revenue was $66.56 million, a decrease of -73.44% compared to the previous year's $250.65 million. Losses were -$746.35 million, 116.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for APLS stock is "Buy." The 12-month stock price forecast is 79.68, which is an increase of 16.66% from the latest price.

Price Target
$79.68
(16.66% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Funct...

WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced new data from the 24-month P...

2 days ago - GlobeNewsWire

Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geograp...

WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that four oral presentations...

2 days ago - GlobeNewsWire

Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its fire...

2 weeks ago - GlobeNewsWire

Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why

Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.

3 weeks ago - Zacks Investment Research

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the...

3 weeks ago - GlobeNewsWire

Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 9.8% Since Last Earnings Report?

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will parti...

1 month ago - GlobeNewsWire

Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS S...

WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced top-line data at 24 months sh...

1 month ago - GlobeNewsWire

10 Stocks Driving the Biotech Resurgence

Barron's screened for stocks such as Global Blood Therapeutics and Karuna Therapeutics that popped this summer.

1 month ago - Barrons

Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down

Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.

1 month ago - Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -2.10% and 4.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results

WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its second quarter 2022 finan...

1 month ago - GlobeNewsWire

Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results

WALTHAM, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a...

2 months ago - GlobeNewsWire

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review

The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.

2 months ago - Zacks Investment Research

Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?

Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could...

2 months ago - Zacks Investment Research

Apellis Surges And Breaks Out As FDA Mulls Its Eye-Disease Treatment

The FDA accepted Apellis Pharmaceuticals' application for an eye-disease treatment on Tuesday, leading APLS stock to surge. The post Apellis Surges And Breaks Out As FDA Mulls Its Eye-Disease Treatment ...

2 months ago - Investors Business Daily

HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals

HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ: APLS) with a Buy rating and a $75 price target. The analyst expects Apellis's C3 inhibitor, pegcetacoplan, to be approved and...

2 months ago - Benzinga

Apellis Pharmaceuticals Stock Jumps After FDA Accepts Drug for Review

Pegcetacoplan aims to treat a cause of blindness that affects more than 1 million Americans.

2 months ago - Barrons

Why Apellis Pharmaceuticals Stock Is Soaring

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher Tuesday after the company announced the U.S. Food and Drug Administration accepted and granted priority review designation for the ne...

2 months ago - Benzinga

Apellis gets Priority Review designation for geographic atrophy therapy

Shares of Apellis Pharmaceuticals Inc. APLS, -2.84% jumped 24.5% in premarket trading on Tuesday after the company said it received a Priority Review designation from the Food and Drug Administration fo...

2 months ago - Market Watch

Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment ...

WALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug A...

2 months ago - GlobeNewsWire

Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting

WALTHAM, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five oral presentations ...

2 months ago - GlobeNewsWire

Apellis (APLS) Expands Deal for Targeted Complement Therapies

Apellis (APLS) expands its current research and development deal with privately held company, Affilogic, to develop targeted complement therapies for delivery into the brain.

3 months ago - Zacks Investment Research

Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for ...

WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today reported new analyses of Phase 3 studies that reinforce th...

3 months ago - GlobeNewsWire